van't Hof AWJ et al. (2008) Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372: 537–546
A report from the Ongoing Tirofiban In Myocardial Infarction Evaluation (On-TIME 2) investigators demonstrates that patients with ST-segment elevation myocardial infarction (STEMI) benefit from early, prehospital treatment with the glycoprotein IIb/IIIa inhibitor tirofiban.
This international, prospective, double-blind trial enrolled patients with acute-onset STEMI who were candidates for percutaneous coronary intervention (PCI). Participants were randomly assigned to receive a 25 µg/kg bolus of tirofiban with a maintenance infusion of 0.15 µg/kg/min for 18 h (n = 491), or matching doses of placebo (n = 493) at first contact with medical personnel. All patients also received aspirin, clopidogrel and unfractionated heparin. Experimental or control drugs were administered in the ambulance in 95% of cases; the median time from symptom onset to medication among these individuals was 75 min. The mean amount of residual ST-segment elevation before (and 1 h after) PCI was significantly lower in patients assigned to tirofiban than in those who received placebo (10.9 versus 12.1 mm, P = 0.028, before PCI and 3.6 versus 4.8 mm, P = 0.003, 1 h after PCI). After 30 days of follow-up, treatment with tirofiban was associated with a reduction in the combined occurrence of death, recurrent STEMI, target-vessel revascularization and emergency use of tirofiban, when compared with placebo (26.0% versus 32.9%, P = 0.02). The incidence of major bleeding did not differ significantly between the two treatment groups.
Rights and permissions
About this article
Cite this article
Early treatment with tirofiban improves outcomes in patients with STEMI. Nat Rev Cardiol 5, 751 (2008). https://doi.org/10.1038/ncpcardio1391
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1391